ClinicalTrials.gg
CompletedNCT05870540Updated Sep 10, 2026Results posted

BPL-003 Efficacy and Safety in Treatment Resistant Depression

A Phase 2 interventional study of BPL-003 and BPL-003 in Treatment Resistant Depression, sponsored by Beckley Psytech Limited. Completed at 42 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Beckley Psytech Limited (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.

Enrollment
34th of 181
196 · median 38
Started
2023
with 11 others
Phase 2
52 of 204
8 open now
Registered
155th of 204
by date

Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 34th largest by enrollment of the 181 interventional ones that give a count, is one of 12 that started in 2023, is one of 52 in phase 2, and was the 155th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

43 of the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).

Read the detailed description

During the main part of the trial, approximately 200 eligible participants will receive a either a low (sub-therapeutic), medium, or high single dose of BPL-003, given intranasally, with 8 weeks of follow-up assessments.

Following this, participants may receive a second high dose of BPL-003 during the OLE, given intranasally as either a single spray or two sprays 10 minutes apart, with another 8 weeks of follow-up assessments.

Psychological support will be given before, during, and after each dose.

03

Conditions studied

  • Treatment Resistant Depression
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of TRD.
  2. History consistent with TRD.
  3. Current depressive episode which is at least moderate in severity (Hamilton Depression Rating Scale score is ≥19 and Clinical Global Impression-Severity score is ≥4).
  4. Willing and able to discontinue current antidepressants, if applicable.

Exclusion criteria

Exclusion criteria:

1. Other co-morbidities.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Low dose (sub-therapeutic)

    Active placebo comparator

    Drug: BPL-003

  • Experimental
    Medium dose

    Drug: BPL-003

  • Experimental
    High dose

    Drug: BPL-003

  • Experimental
    Monophasic

    Drug: BPL-003

  • Experimental
    Biphasic

    Drug: BPL-003

Interventions

  • A single dose administered intranasally

  • A single dose administered intranasally (administered as 2 nasal sprays, 10 minutes apart)

06

What researchers measure

Primary outcomes

  1. Core: Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Day 29 (12 mg vs 0.3 mg BPL-003)

    The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 12 mg (high dose) vs 0.3 mg (low dose) BPL-003 at Day 29 was assessed.

    Time frame: 4 weeks

  2. OLE: Number of Participants With Treatment-emergent Adverse Events in the OLE

    The safety of a second dose of BPL-003 given with psychological support to participants with TRD was assessed by the number and percentage of participants with treatment-emergent adverse events.

    Time frame: 8 weeks

Secondary outcomes

  1. Core: Change From Baseline in MADRS Total Score at Day 8 (12 mg vs 0.3 mg BPL-003)

    The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 12 mg (high dose) vs 0.3 mg (low dose) BPL-003 at Day 8 was assessed.

    Time frame: 1 week

  2. Core: Change From Baseline in MADRS Total Score at Day 29 (8 mg vs 0.3 mg BPL-003)

    The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 8 mg (medium dose) vs 0.3 mg (low dose) BPL-003 at Day 29 was assessed.

    Time frame: 4 weeks

  3. Core: Change From Baseline in MADRS Total Score at Day 8 (8 mg vs 0.3 mg BPL-003)

    The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 8 mg (medium dose) vs 0.3 mg (low dose) BPL-003 at Day 8 was assessed.

    Time frame: 1 week

  4. Core: Number of Participants With Treatment-emergent Adverse Events in the Core Trial Period

    The safety of BPL-003 given with psychological support to participants with TRD was assessed by the number and percentage of participants with treatment-emergent adverse events. Any clinically significant findings during the trial have been included as adverse events.

    Time frame: 8 weeks

07

Results

Posted Sep 10, 2026
Limitations and caveats
Core randomization was 1:1:1 and was modified to 3:1:3 in protocol version 3.0 (17 May 24) to enable recruitment to complete, reducing trial numbers from 225 to 203 participants. This reduced the numbers in the 8 mg arm but maintained the numbers in the 0.3 mg and 12 mg arms, preserving the power of the primary endpoint comparison. Overall randomization allocation ratio averaged to approximately 3:2:3. 5 SAEs reported, only 1 (suicidal ideation) was considered related to study drug.

Participant flow

Participants were recruited to the study between 14-Sep-2023 and 20-Jan-2025.

Core trial period
Participant flow — Core trial period
MilestoneCore: Low Dose (0.3 mg)Core: Medium Dose (8 mg)Core: High Dose (12 mg)OLE: Monophasic Dosing (12 mg)OLE: Biphasic Dosing (4 mg and 8 mg)
Started74467300
Completed64416900
Not completed105400
OLE trial period
Participant flow — OLE trial period
MilestoneCore: Low Dose (0.3 mg)Core: Medium Dose (8 mg)Core: High Dose (12 mg)OLE: Monophasic Dosing (12 mg)OLE: Biphasic Dosing (4 mg and 8 mg)
Started0005354
Completed0004847
Not completed00057

Outcome measures

PrimaryCore: Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Day 29 (12 mg vs 0.3 mg BPL-003)

The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 12 mg (high dose) vs 0.3 mg (low dose) BPL-003 at Day 29 was assessed.

Time frame:
4 weeks
Reported as:
Least squares mean · Units on a scale
Core: Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Day 29 (12 mg vs 0.3 mg BPL-003)
Units on a scaleCore: Low Dose (0.3 mg)Core: High Dose (12 mg)
Core: Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Day 29 (12 mg vs 0.3 mg BPL-003)-5.8 ± 1.28-11.2 ± 1.27
Statistical analysis
  • Core: Low Dose (0.3 mg) vs Core: High Dose (12 mg) · Mixed Models Analysis · p = 0.0033 · Least square means: -5.3 · 95% CI -8.9 to -1.8
PrimaryOLE: Number of Participants With Treatment-emergent Adverse Events in the OLE

The safety of a second dose of BPL-003 given with psychological support to participants with TRD was assessed by the number and percentage of participants with treatment-emergent adverse events.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
OLE: Number of Participants With Treatment-emergent Adverse Events in the OLE
ParticipantsOLE: Monophasic Dosing (12 mg)OLE: Biphasic Dosing (12 mg)
OLE: Number of Participants With Treatment-emergent Adverse Events in the OLE4646
SecondaryCore: Change From Baseline in MADRS Total Score at Day 8 (12 mg vs 0.3 mg BPL-003)

The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 12 mg (high dose) vs 0.3 mg (low dose) BPL-003 at Day 8 was assessed.

Time frame:
1 week
Reported as:
Least squares mean · Units on a scale
Core: Change From Baseline in MADRS Total Score at Day 8 (12 mg vs 0.3 mg BPL-003)
Units on a scaleCore: Low Dose (0.3 mg)Core: High Dose (12 mg)
Core: Change From Baseline in MADRS Total Score at Day 8 (12 mg vs 0.3 mg BPL-003)-4.7 ± 1.20-10.9 ± 1.19
Statistical analysis
  • Core: Low Dose (0.3 mg) vs Core: High Dose (12 mg) · Mixed Models Analysis · p = 0.0003 · Least square means: -6.2 · 95% CI -9.5 to -2.8
SecondaryCore: Change From Baseline in MADRS Total Score at Day 29 (8 mg vs 0.3 mg BPL-003)

The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 8 mg (medium dose) vs 0.3 mg (low dose) BPL-003 at Day 29 was assessed.

Time frame:
4 weeks
Reported as:
Least squares mean · Units on a scale
Core: Change From Baseline in MADRS Total Score at Day 29 (8 mg vs 0.3 mg BPL-003)
Units on a scaleCore: Low Dose (0.3 mg)Core: Medium Dose (8 mg)
Core: Change From Baseline in MADRS Total Score at Day 29 (8 mg vs 0.3 mg BPL-003)-5.8 ± 1.28-12.0 ± 1.61
Statistical analysis
  • Core: Low Dose (0.3 mg) vs Core: Medium Dose (8 mg) · Mixed Models Analysis · p = 0.0032 · Least square means: -6.2 · 95% CI -10.2 to -2.1
SecondaryCore: Change From Baseline in MADRS Total Score at Day 8 (8 mg vs 0.3 mg BPL-003)

The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 8 mg (medium dose) vs 0.3 mg (low dose) BPL-003 at Day 8 was assessed.

Time frame:
1 week
Reported as:
Least squares mean · Units on a scale
Core: Change From Baseline in MADRS Total Score at Day 8 (8 mg vs 0.3 mg BPL-003)
Units on a scaleCore: Low Dose (0.3 mg)Core: Medium Dose (8 mg)
Core: Change From Baseline in MADRS Total Score at Day 8 (8 mg vs 0.3 mg BPL-003)-4.7 ± 1.20-11.0 ± 1.52
Statistical analysis
  • Core: Low Dose (0.3 mg) vs Core: Medium Dose (8 mg) · Mixed Models Analysis · p = 0.0014 · Least square means: -6.3 · 95% CI -10.1 to -2.5
SecondaryCore: Number of Participants With Treatment-emergent Adverse Events in the Core Trial Period

The safety of BPL-003 given with psychological support to participants with TRD was assessed by the number and percentage of participants with treatment-emergent adverse events. Any clinically significant findings during the trial have been included as adverse events.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Core: Number of Participants With Treatment-emergent Adverse Events in the Core Trial Period
ParticipantsCore: Low Dose (0.3 mg)Core: Medium Dose (8 mg)Core: High Dose (12 mg)
Core: Number of Participants With Treatment-emergent Adverse Events in the Core Trial Period543562

Adverse events

Collected over Core period: 8 weeks; OLE period: 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Core: Low Dose (0.3 mg)0/74 (0%)1/74 (1.4%)54/74 (73%)
Core: Medium Dose (8 mg)0/46 (0%)1/46 (2.2%)35/46 (76.1%)
Core: High Dose (12 mg)0/73 (0%)0/73 (0%)62/73 (84.9%)
OLE: Monophasic Dosing (12 mg)0/53 (0%)2/53 (3.8%)46/53 (86.8%)
OLE: Biphasic Dosing (4 mg or 12 mg)0/54 (0%)1/54 (1.9%)39/54 (72.2%)
Most frequent serious events
Most frequent serious events
EventCore: Low Dose (0.3 mg)Core: Medium Dose (8 mg)Core: High Dose (12 mg)OLE: Monophasic Dosing (12 mg)OLE: Biphasic Dosing (4 mg or 12 mg)
AgitationPsychiatric disorders0/741/460/730/530/54
Suicidal ideationPsychiatric disorders0/740/460/731/531/54
Binge drinkingPsychiatric disorders0/740/460/731/530/54
DepressionPsychiatric disorders1/740/460/730/530/54
Most frequent other events
Showing 10 of 34
Most frequent other events
EventCore: Low Dose (0.3 mg)Core: Medium Dose (8 mg)Core: High Dose (12 mg)OLE: Monophasic Dosing (12 mg)OLE: Biphasic Dosing (4 mg or 12 mg)
NauseaGastrointestinal disorders2/7415/4629/7320/5314/54
HeadacheNervous system disorders21/7412/4624/7316/5313/54
AnxietyPsychiatric disorders6/742/4612/7313/534/54
Administration site painGeneral disorders6/748/4616/739/539/54
Administration site discomfortGeneral disorders2/745/4612/737/5311/54
Blood pressure increasedInvestigations3/746/4612/735/538/54
VomitingGastrointestinal disorders3/746/469/734/538/54
InsomniaPsychiatric disorders6/741/469/735/535/54
FatigueGeneral disorders0/741/464/734/536/54
Psychomotor hyperactivityNervous system disorders0/740/464/735/536/54

Baseline characteristics

The overall trial population comprised 300 participants, including 193 participants in the Core trial period, of whom 107 continued into the OLE trial period. Baseline characteristics are presented for the full analysis set (FAS) for each trial period, defined as all participants who were randomized and received at least 1 dose of trial medication during the respective trial period. The FAS comprises 193 participants for the Core Trial Period and 107 participants for the OLE trial period.

Age, Continuous
Age, Continuous(Years)Core: Low Dose (0.3 mg)Core: Medium Dose (8 mg)Core: High Dose (12 mg)OLE: Monophasic Dosing (12 mg)OLE: Biphasic Dosing (4 mg and 8 mg)Total
Core trial period41.0 ± 11.1740.6 ± 12.1041.2 ± 10.59——41.2 ± 11.13
OLE trial period———40.4 ± 9.1039.6 ± 10.9540.0 ± 10.04
Sex: Female, Male
Sex: Female, Male(Participants)Core: Low Dose (0.3 mg)Core: Medium Dose (8 mg)Core: High Dose (12 mg)OLE: Monophasic Dosing (12 mg)OLE: Biphasic Dosing (4 mg and 8 mg)Total
Core trial period — Female44274300114
Core trial period — Male3019300079
OLE trial period — Female000293362
OLE trial period — Male000242145
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Core: Low Dose (0.3 mg)Core: Medium Dose (8 mg)Core: High Dose (12 mg)OLE: Monophasic Dosing (12 mg)OLE: Biphasic Dosing (4 mg and 8 mg)Total
Core trial period — American Indian or Alaska Native000000
Core trial period — Asian3350011
Core trial period — Native Hawaiian or Other Pacific Islander000000
Core trial period — Black or African American4510010
Core trial period — White67386600171
Core trial period — More than one race001001
Core trial period — Unknown or Not Reported000000
OLE trial period — American Indian or Alaska Native000000
OLE trial period — Asian000033
OLE trial period — Native Hawaiian or Other Pacific Islander000000
OLE trial period — Black or African American000123
OLE trial period — White0005149100
OLE trial period — More than one race000101
OLE trial period — Unknown or Not Reported000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Core: Low Dose (0.3 mg)Core: Medium Dose (8 mg)Core: High Dose (12 mg)OLE: Monophasic Dosing (12 mg)OLE: Biphasic Dosing (4 mg and 8 mg)Total
Core trial period — Hispanic or Latino6330012
Core trial period — Not Hispanic or Latino68437000181
Core trial period — Unknown or Not Reported000000
OLE trial period — Hispanic or Latino000516
OLE trial period — Not Hispanic or Latino0004853101
OLE trial period — Unknown or Not Reported000000
08

Study locations

42 sites
  • UAB School of Public Health, Department of Health Behavior
    Birmingham, Alabama 35209, United States
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • Kadima Neuropsychiatry Institute
    San Diego, California 92037, United States
  • San Francisco Insight and Integration Center
    San Francisco, California 94114, United States
  • Pacific Neuroscience Institute, Treatment and Research in Psychedelics (TRIP) Program
    Santa Monica, California 90404, United States
  • Wholeness Center
    Fort Collins, Colorado 80525, United States
  • Segal Trials Center for Psychedelic and Cannabis Research
    Lauderhill, Florida 33319, United States
  • Emory University, Brain Health Center, Department of Psychiatry and Behavioral Sciences
    Atlanta, Georgia 30329, United States
  • CenExel ACMR
    Atlanta, Georgia 30331, United States
  • CenExel iResearch
    Decatur, Georgia 30030, United States
  • Sunstone Medical PC (Sunstone Therapies / Aquilino Cancer Center)
    Rockville, Maryland 20850, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • CenExel HRI
    Berlin, New Jersey 08009, United States
  • New York State Psychiatric Institute
    New York, New York 10032, United States
  • Portland Psychotherapy
    Portland, Oregon 97227, United States
  • Insite clinical research
    DeSoto, Texas 75115, United States
  • AIM Trials
    Plano, Texas 75093, United States
  • Cedar Clinical Research
    Draper, Utah 84020, United States
  • University of Wisconsin, Dept of Family Medicine & Community Health
    Madison, Wisconsin 53705, United States
  • Royal Prince Alfred Hospital
    Sydney, New South Wales 2050, Australia
  • Dept. of Psychiatry and School Psychological Sciences, Monash University
    Clayton, Victoria 3168, Australia
  • NeuroCentrix Research
    Melbourne, 3053, Australia
  • Royal Melbourne Hospital, University of Melbourne
    Parkville, 3050, Australia
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • OVID Clinic, Augmented Psychotherapy
    Berlin, 10247, Germany
  • Department of Psychiatry, University Hospital Frankfurt
    Frankfurt am Main, 60528, Germany
  • Central Institute of Mental Health, Dept. of Molecular Neuroimaging
    Mannheim, 68159, Germany
  • Universitätsklinik für Psychiatrie und Psychotherapie, Calwerstr. 14
    Tübingen, 72076, Germany
  • Department of Psychiatry, UCK
    Gdansk, 80-214, Poland
  • Centrum Badań Klinicznych PI-House sp. z o.o.
    Gdansk, 80-546, Poland
  • SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi
    Lodz, 92-216, Poland
  • Klinika Inventiva
    Tuszyn, 95-080, Poland
  • Department of Pharmacology and Physiology of CNS
    Warsaw, 02-957, Poland
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Parc Sanitari Sant Joan de Deu HD Numancia
    Barcelona, 08029, Spain
  • Hospital Clinic de Barcelona, Psychiatry and Psychology Dept.
    Barcelona, 08036, Spain
  • Fundación de Investigación HM Hospital
    Madrid, 28050, Spain
  • Centro de Salud Mental La Corredoria
    Oviedo, 33011, Spain
  • Centro Salud San Juan
    Salamanca, 37005, Spain
  • NIHR Exeter Clinical Research Facility
    Exeter, EX2 5DW, United Kingdom
  • King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN) - Centre for Affective Disorders (CfAD)
    London, SE5 8AF, United Kingdom
  • Clerkenwell Health
    London, W1G 8DR, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Due to the GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Mar 2025, 18 months.

Results were first posted in Sep 2026, 1 year 5 months after primary completion.

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2023
First posted
May 23, 2023
StartActual
Sep 14, 2023
Primary completionActual
Mar 28, 2025
CompletionActual
Jul 3, 2025
Results first posted
Sep 10, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05870540
Responsible party
Sponsor
First posted
May 23, 2023
Start date
Sep 14, 2023
Primary completion
Mar 28, 2025
Completion
Jul 3, 2025
Results posted
Sep 10, 2026
Last update
Sep 10, 2026

Study contacts

Kevin Craig, M.D.
study director · Beckley Psytech Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BPL-003

Start the discussion